Prosecution Insights
Last updated: May 29, 2026

Examiner: ZEMAN, ROBERT A

Tech Center 1700 • Art Units: 1645 1792

This examiner grants 54% of resolved cases

Performance Statistics

54.0%
Allow Rate
-11.0% vs TC avg
831
Total Applications
+27.8%
Interview Lift
1343
Avg Prosecution Days
Based on 771 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
17.1%
§102 Novelty
34.3%
§103 Obviousness
45.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17914274 ANTI-ACINETOBACTER BAUMANNII POLYCLONAL ANTIBODY (AB-pAb), AND USES THEREOF Final Rejection The Regents of the University of California
18266625 MICROORGANISM THAT PRODUCES USEFUL SUBSTANCE AND METHOD FOR PRODUCING USEFUL SUBSTANCE Non-Final OA KANEKA CORPORATION
18322442 METHODS FOR DIAGNOSING GASTRIC INTESTINAL METAPLASIA Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
18153727 STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF Non-Final OA NEW YORK UNIVERSITY
18995578 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS FOR ALLEVIATING PARKINSON'S DISEASE AND USE THEREOF Non-Final OA WECARE PROBIOTICS CO., LTD.
18566194 BACTERIAL STRAINS FOR USE IN PREVENTING, TREATING AND/OR REDUCING SYMPTOMS ASSOCIATED WITH A RHINOVIRUS-INDUCED COLD INFECTION Non-Final OA International N&H Denmark APS
18191919 Bifidobacterium longum for Preventing and/or Treating Essential Hypertension Final Rejection Jiangnan University
18607330 BACILLUS SUBTILIS ZF-1 AND APPLICATION THEREOF IN INHIBITING AFRICAN SWINE FEVER VIRUS Non-Final OA Wuhan Keqian Biology Co., Ltd.
18008797 METHOD OF INCREASING NISIN PRODUCTION IN LACTOCOCCUS LACTIS Non-Final OA Chr. Hansen A/S
16347861 DNA ANTIBODY CONSTRUCTS FOR USE AGAINST LYME DISEASE Final Rejection THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
17641031 COMBINATION VACCINE FOR INTRADERMAL ADMINISTRATION Non-Final OA INTERVET INC.
18392590 TREATMENT OF CANCER USING BOTULINUM TOXIN AND NITROUS OXIDE Non-Final OA Penland Foundation
18571132 BROAD SPECTRUM PATHOGEN CONTROL IN PLANTS Non-Final OA FUNDACIÓN CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA, MEDINA
18479501 PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUS Non-Final OA Evaxion Biotech A/S
18038901 BIOMARKERS FOR MYCOBACTERIUM AVIUM PARATUBERCULOSIS Non-Final OA ABERYSTWYTH UNIVERSITY
18256547 AGRICULTURAL FORMULATION COMPRISING AT LEAST ONE BACTERIAL STRAIN B. SAFENSIS RGM 2450, AND/OR A BACTERIAL STRAIN B. SIAMENSIS RGM 2529 AND AGRICULTURAL EXCIPIENTS; USE OF THE FORMULATION AND METHOD FOR STIMULATING GROWTH AND/OR INCREASING CROP YIELDS AND/OR PROTECTING CROPS AGAINST DISEASES AND PESTS Non-Final OA BLANES SPA
17758139 IMMUNOTHERAPEUTIC TREATMENT OF CANCER Final Rejection IMMODULON THERAPEUTICS LIMITED
18033232 LACTIC ACID BACTERIUM FOR TREATMENT OF AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY Final Rejection Su Ching HU
18027614 NOVEL LACTIC ACID BACTERIA ISOLATED FROM AGED MEAT, AND USE THEREOF Final Rejection KOOKMINBIO, CORP.
17896847 COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH HYPERPROLIFERATIVE CELLULAR DIVISION, DIABETES, IMMUNODEFICIENCY DISEASES, ALZHEIMER'S DISEASE OR AUTOIMMUNE DISEASES, AND TESTING SYSTEM AND METHOD Final Rejection Chai Foundation for Medical Research & Life Extension, Inc.
17779676 COMPOSITIONS FOR IMPROVING ATHLETIC PERFORMANCE AND METHODS OF USE THEREOF Non-Final OA FITBIOMICS INC.
17627796 Novel Xanthomonas Strains and Related Methods Non-Final OA Geoffrey Gardiner Dairy Foundation Limited
16475541 USE OF THE CPCR REGULATOR GENE FOR OBTAINING NEW RECOMBINANT STRAINS OF BACILLUS THURINGIENSIS WITH REDUCED SPORULATION CAPACITY Final Rejection Institute of Plant Protection, Chinese Academy of Agricultural Sciences

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month